Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 16/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228138 | 0.91 | ADK (0.51) | ADKPRMT5WDR77METTL3DNMT1 | |
| SCHEMBL31228198 | 0.76 | ADK (0.57) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL31228504 | 0.75 | ADK (0.47) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL16214128 | 0.75 | AHCY (0.54) | PRMT5WDR77 | |
| SCHEMBL31228199 | 0.75 | ADK (0.40) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL29548998 | 0.73 | AHCY (0.59) | PRMT5WDR77 | |
| SCHEMBL13523527 | 0.73 | AHCY (0.59) | PRMT5WDR77 | |
| SCHEMBL13471035 | 0.72 | ADORA2A (0.48) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL16214138 | 0.72 | SLC28A1 (0.48) | — | |
| SCHEMBL31228134 | 0.72 | ADK (0.55) | ADKPRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024227159-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |